AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|
11 C
New York
Monday, October 26, 2026

Tag: aromatase inhibitor

newsFORsourcecompanycontentinformation1releasesmarket

HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial

Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of...

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line...

BRC Therapeutics Appoints Ron Eastman to Board of Directors

Veteran Pharma Executive and Healthcare Investor Brings More Than 40 Years of Drug Development, Operations and Investment ExperienceMONTEREY, Calif., June 12, 2026 /PRNewswire/ -- BRC...

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Data from Orbit and Cosmic studies expected around the end of the year 
Data from Orbit and Cosmic studies expected around the end of the year

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...

ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility

LAUSANNE, Switzerland and COPENHAGEN, Denmark, July 01, 2025 (GLOBE NEWSWIRE) -- ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that the first participant has been included in the company’s Phase 2 clinical trial of its lead candidate RPN-001 (leflutrozole), an orally administered aromatase inhibitor in development for the treatment of male infertility (https://clinicaltrials.gov/study/NCT06993155?term=Leflutrozole&rank=1).

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAromatase inhibitor

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers